Vanguard Fiduciary Trust
ALNY icon

Vanguard Fiduciary Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260M Buy
862,782
+21,894
+3% +$6.6M 0.06% 284
2026
Q1 		$278M Buy
+840,888
New +$286M 0.07% 251

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust's ALNY Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Alnylam Pharmaceuticals (ALNY) stake by 2.6% in Q2 2026, buying an estimated $6.6M and bringing the position to 862,782 shares worth $260M. The position accounts for 0.06% of the portfolio, ranked #284.

Vanguard Fiduciary Trust first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $278M in Q1 2026. 777 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Vanguard Fiduciary Trust held 862,782 shares of Alnylam Pharmaceuticals worth $260M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 21,894 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.6M.
  • Alnylam Pharmaceuticals made up 0.06% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #284 holding.
  • Vanguard Fiduciary Trust first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Alnylam Pharmaceuticals position peaked at $278M in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.